Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs US Bancorp — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while US Bancorp trades at $56.26 (market cap $88.64B). The key difference: US Bancorp is far larger — about 11.8× Spyre Therapeutics Inc. Common Stock's market cap, and US Bancorp pays a 3.8% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and US Bancorp for 98 Days on average.
| SYRE | USB | |
|---|---|---|
Market Cap | $7.52B | $88.64B |
Volume | 1,441,031 | 8,200,583 |
Sector | Health | Financials |
52-Week High | $108.92 | $65.42 |
52-Week Low | $22.18 | $45.47 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $6.52B | $118.14B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
U.S. Bancorp (USB) trades at $56.89, down 0.92% with bearish technical signals but strong fundamentals including consistent earnings beats and a 27.61% net margin. The stock shows a P/E of 11.36 and ROE of 13.53%, with analyst consensus at Buy (51%) and a $69.94 price target. Recent news highlights dividend increases and strong Q3 expectations for net interest income and fee revenues.
Outlook remains positive based on valuation and earnings momentum, though risks include regulatory changes and interest rate sensitivity. The 3.8% dividend hike to $0.54 signals management confidence, but investors should monitor net cash flow trends and competitive pressures in regional banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
